Detalles de la búsqueda
1.
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
Blood
; 140(8): 839-850, 2022 08 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-35605176
2.
The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study.
Haematologica
; 107(1): 134-142, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33327712
3.
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med
; 378(12): 1107-1120, 2018 Mar 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-29562156
4.
Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.
Blood Adv
; 8(8): 1992-2004, 2024 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38290108
5.
A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies.
EJHaem
; 3(2): 492-506, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35846043
6.
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
Lancet Haematol
; 9(3): e190-e199, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35240075
7.
Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy.
EJHaem
; 2(2): 266-271, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35845292
8.
Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study.
Clin Cancer Res
; 27(17): 4690-4695, 2021 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34083230
9.
Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study.
Leuk Lymphoma
; 61(1): 56-65, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31549889
10.
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.
J Clin Oncol
; 38(34): 4042-4054, 2020 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32986498
11.
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
J Clin Oncol
; 37(4): 269-277, 2019 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30523712
12.
Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study.
Clin Pharmacokinet
; 58(12): 1621-1634, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31209657
13.
Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer.
Clin Lung Cancer
; 18(1): 43-49, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27461773
14.
Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer.
Clin Lung Cancer
; 18(1): 50-59, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27856142
15.
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen.
Blood Adv
; 6(15): 4553-4557, 2022 08 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35736670
16.
Caffeine as a performance-enhancing drug in rats: sex, dose, housing, and task considerations.
Percept Mot Skills
; 97(1): 259-70, 2003 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-14604049
17.
[Toward pertinent analytical objectives for haematological parameters]. / Vers les objectifs analytiques pertinents pour les paramètres de l'hémogramme.
Ann Biol Clin (Paris)
; 72(6): 705-14, 2014.
Artículo
en Francés
| MEDLINE | ID: mdl-25486666
18.
Prolonged latent schistosomiasis diagnosed 38 years after infestation in a HIV patient.
Scand J Infect Dis
; 38(6-7): 572-5, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-16798718
Resultados
1 -
18
de 18
1
Próxima >
>>